Your browser doesn't support javascript.
loading
The context-specific role of germline pathogenicity in tumorigenesis.
Srinivasan, Preethi; Bandlamudi, Chaitanya; Jonsson, Philip; Kemel, Yelena; Chavan, Shweta S; Richards, Allison L; Penson, Alexander V; Bielski, Craig M; Fong, Christopher; Syed, Aijazuddin; Jayakumaran, Gowtham; Prasad, Meera; Hwee, Jason; Sumer, Selcuk Onur; de Bruijn, Ino; Li, Xiang; Gao, JianJiong; Schultz, Nikolaus; Cambria, Roy; Galle, Jesse; Mukherjee, Semanti; Vijai, Joseph; Cadoo, Karen A; Carlo, Maria I; Walsh, Michael F; Mandelker, Diana; Ceyhan-Birsoy, Ozge; Shia, Jinru; Zehir, Ahmet; Ladanyi, Marc; Hyman, David M; Zhang, Liying; Offit, Kenneth; Robson, Mark E; Solit, David B; Stadler, Zsofia K; Berger, Michael F; Taylor, Barry S.
Affiliation
  • Srinivasan P; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Bandlamudi C; Stanford University School of Medicine, Palo Alto, CA, USA.
  • Jonsson P; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Kemel Y; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Chavan SS; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Richards AL; Robert and Kate Niehaus Center for Inherited Cancer Genomics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Penson AV; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Bielski CM; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Fong C; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Syed A; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Jayakumaran G; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Prasad M; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Hwee J; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Sumer SO; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • de Bruijn I; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Li X; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Gao J; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Schultz N; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Cambria R; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Galle J; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Mukherjee S; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Vijai J; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Cadoo KA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Carlo MI; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Walsh MF; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Mandelker D; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Ceyhan-Birsoy O; Research and Technology Management, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Shia J; Research and Technology Management, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Zehir A; Robert and Kate Niehaus Center for Inherited Cancer Genomics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Ladanyi M; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Hyman DM; Robert and Kate Niehaus Center for Inherited Cancer Genomics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Zhang L; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Offit K; Robert and Kate Niehaus Center for Inherited Cancer Genomics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Robson ME; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Solit DB; Robert and Kate Niehaus Center for Inherited Cancer Genomics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Stadler ZK; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Berger MF; Robert and Kate Niehaus Center for Inherited Cancer Genomics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Taylor BS; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nat Genet ; 53(11): 1577-1585, 2021 11.
Article in En | MEDLINE | ID: mdl-34741162
ABSTRACT
Human cancers arise from environmental, heritable and somatic factors, but how these mechanisms interact in tumorigenesis is poorly understood. Studying 17,152 prospectively sequenced patients with cancer, we identified pathogenic germline variants in cancer predisposition genes, and assessed their zygosity and co-occurring somatic alterations in the concomitant tumors. Two major routes to tumorigenesis were apparent. In carriers of pathogenic germline variants in high-penetrance genes (5.1% overall), lineage-dependent patterns of biallelic inactivation led to tumors exhibiting mechanism-specific somatic phenotypes and fewer additional somatic oncogenic drivers. Nevertheless, 27% of cancers in these patients, and most tumors in patients with pathogenic germline variants in lower-penetrance genes, lacked particular hallmarks of tumorigenesis associated with the germline allele. The dependence of tumors on pathogenic germline variants is variable and often dictated by both penetrance and lineage, a finding with implications for clinical management.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Germ-Line Mutation / Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Nat Genet Journal subject: GENETICA MEDICA Year: 2021 Document type: Article Affiliation country: Publication country: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Germ-Line Mutation / Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Nat Genet Journal subject: GENETICA MEDICA Year: 2021 Document type: Article Affiliation country: Publication country: EEUU / ESTADOS UNIDOS / ESTADOS UNIDOS DA AMERICA / EUA / UNITED STATES / UNITED STATES OF AMERICA / US / USA